MD Anderson and Eisbach Bio collaborate to develop precision oncology drugs

The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly discover and develop precision oncology drugs that target synthetic lethal engines key to tumor genome evolution.

Related Keywords

Texas ,United States ,Eisbach Bio Gmb ,Andreas Ladurner ,Timothya Yap ,Adrian Schomburg ,Philip Jones ,Emily Henderson ,Institute For Applied Cancer Science ,University Of Texas Md Anderson Cancer Center ,Cancer Center ,Eisbach Bio Gmbh ,Therapeutics Discovery ,Investigational Cancer Therapeutics ,Applied Cancer Science ,Oncology ,Essay ,Dancer ,Na ,Dna Damage ,Drug Discovery ,Drugs ,Revolution ,Gene ,Enetic ,Enome ,Genomics ,Olecule ,Mh ,Research ,Herapeutics ,Humor ,